Skip to main content
Article thumbnail
Location of Repository

Growth factors in idiopathic pulmonary fibrosis: relative roles

By JT Allen and MA Spiteri

Abstract

Treatment of idiopathic pulmonary fibrosis patients has evolved very slowly; the fundamental approach of corticosteroids alone or in combination with other immunosuppressive agents has had little impact on long-term survival. The continued use of corticosteroids is justified because of the lack of a more effective alternative. Current research indicates that the mechanisms driving idiopathic pulmonary fibrosis reflect abnormal, dysregulated wound healing within the lung, involving increased activity and possibly exaggerated responses by a spectrum of profibrogenic growth factors. An understanding of the roles of these growth factors, and the way in which they modulate events at cellular level, could lead to more targeted therapeutic strategies, improving patients' quality of life and survival

Topics: R1, health_and_wellbeing
Publisher: BioMed Central
OAI identifier: oai:usir.salford.ac.uk:123

Suggested articles

Citations

  1. (1999). A Fas pathway to pulmonary fibrosis.
  2. (2001). A: Distinct patterns of insulin-like growth factor binding protein (IGFBP)-2 and IGFBP-3 expression in oxidant exposed lung epithelial cells. Biochim Biophys Acta
  3. (1998). A: Expression of insulin-like growth factors and their binding proteins by bronchoalveolar cells from children with and without interstitial lung disease. Eur Respir J
  4. (2000). A: The Fas/Fas ligand system is not required for bleomycin-induced pulmonary fibrosis in mice.
  5. (2000). A: Tumour necrosis factor-alpha suppresses the induction of connective tissue growth factor by transforming growth factor-beta in normal and scleroderma fibroblasts.
  6. (2001). AB: SMAD3 KO mouse is resistant to gene based TGF-beta1 induced fibrosis: Lack of activation of CTGF [abstract].
  7. (2000). BC: Hepatocyte growth factor attenuates collagen accumulation in a murine model of pulmonary fibrosis.
  8. (1995). Chung KF: Insulin-like growth factor I is a major fibroblast mitogen produced by primary cultures of human airway epithelial cells. Clin Sci
  9. (1995). Cultured lung fibroblasts isolated from patients with idiopathic pulmonary fibrosis have a diminshed capacity to synthesise prostaglandin E2 and to express cyclooxygenase-2.
  10. (1995). Cytoskeletal protein modulation in pulmonary alveolar myofibroblasts during idiopathic pulmonary fibrosis. Possible role of transforming growth factor beta and tumor necrosis factor alpha. Am J Respir Crit Care Med
  11. (2000). Di Giovine F: Increased risk of fibrosing alveolitis associated with interleukin-1 receptor antagonist and tumor necrosis factor-α gene polymorphisms. Am J Respir Crit Care Med
  12. (1999). Differential immunolocalisation of VEGF in rat and human adult lung, and in experimental rat lung fibrosis: light, fluorescence, and electron microscopy. Anat Rec
  13. (2001). Differential mRNA expression of insulin-like growth factor-1 splice variants in patients with idiopathic pulmonary fibrosis and pulmonary sarcoidosis.
  14. (2001). DM: Role of endothelin-1 in lung disease. Respir Res
  15. (1999). Enhanced insulin-like growth factor binding protein-related protein 2 (connective tissue growth factor) expression in patients with idiopathic pulmonary fibrosis and pulmonary sarcoidosis.
  16. (1993). Expression and localisation of tumor necrosis factor-alpha and its mRNA in idiopathic pulmonary fibrosis.
  17. (2001). FJ: Steroids in pulmonary fibrosis: A perspective assessment of adverse reactions, response to therapy, and survival.
  18. (1997). Giaid A: Elevated expression of endothelin-1 and endothelin-converting enzyme-1 in idiopathic pulmonary fibrosis: possible involvement of proinflammatory cytokines.
  19. (1997). GJ: The pathogenesis of pulmonary fibrosis: is there a fibrosis gene?
  20. (2000). GL: Vascular endothelial growth factor induces expression of connective tissue growth factor via KDR, Flt1, and phosphatidylinositol 3-kinase-akt-dependent pathways in retinal vascular cells.
  21. (2001). Goldschmeding R: Identification of human ccn2 (connective tissue growth factor) promoter polymorphisms. J Clin Pathol Mol Pathol
  22. (1991). Greenberg AH: Increased production and immunohistochemical localisation of transforming growth factor-β in idiopathic pulmonary fibrosis.
  23. (2001). Hara N: Attenuation of bleomycin-induced pneumopathy in mice by a caspase inhibitor.
  24. (1999). Hara N: Essential roles of the Fas–Fas ligand pathway in the development of pulmonary fibrosis.
  25. (1996). Haroske G: Alterations in the alveolar epithelium after injury leading to pulmonary fibrosis. Histol Histopathol
  26. (1999). Hutchinson IV: CA repeat allele polymorphism in the first intron of the human interferon-gamma gene is associated with lung allograft fibrosis. Hum Immunol
  27. (1999). Immunoreactive interleukin 4 and interferon-gamma expression by type II alveolar epithelial cells in interstitial lung disease.
  28. (2000). Inhaled beclomethasone and colchicine (IBC) versus inhaled beclomethasone, colchicine and captopril (IBCCAP) in patients with idiopathic pulmonary fibrosis (IPF) [abstract]. Am J Respir Crit Care Med
  29. (2000). Interstitial fibrosis and growth factors. Environ Health Perspect
  30. (1998). IV: Genotypic variation in the transforming growth factor-beta1 gene: association with transforming growth factor-beta1 production, fibrotic lung disease, and graft fibrosis after lung transplantation. Transplantation
  31. (2001). King TE Jr: Treatment of idiopathic pulmonary fibrosis: The rise and fall of corticosteroids.
  32. (1999). L-H: A preliminary study of long term treatment with interferon gamma1b and low dose prednisolone in patients with idiopathic pulmonary fibrosis.
  33. (1995). Localisation of platelet-derived growth factor and insulin-like growth factor I in the fibrotic lung. Am J Respir Crit Care Med
  34. (1999). Mageto Y: Treatment of idiopathic pulmonary fibrosis with a new antifibrotic agent, pirfenidone: results of a prospective, open-label phase II study. Am J Respir Crit Care Med
  35. (1998). Myers JL: Idiopathic pulmonary fibrosis. Clinical relevance of pathologic classification.
  36. (2000). N: Different expression of TNF-α receptors and prostaglandin E2 production in normal and fibrotic lung fibroblasts. Potential implications for the evolution of the inflammatory process.
  37. (2001). Pardo A: Fibroblasts from idiopathic pulminary fibrosis and normal lungs differ in growth rate, apoptosis, and tissue inhibitor of metalloproteinases expression.
  38. (2001). Pardo A: Idiopathic pulmonary fibrosis: Prevailing and evolving hypotheses about its pathogenesis and implications for therapy. Ann Intern Med
  39. (1999). Phan SH: Inhibition of myofibroblast apoptosis by transforming growth factor β1.
  40. (1999). Regulation of connective tissue growth factor expression by prostaglandin E2.
  41. (1999). RM: IFN-γ-inducible protein 10 attenuates bleomycin-induced pulmonary fibrosis via inhibition of angiogenesis.
  42. (1997). RP: Increased endothelin-1 in bleomycin-induced pulmonary fibrosis and the effect of an endothelin receptor antagonist. Am J Respir Crit Care Med
  43. (1995). SE: A type 2 (Th2-like) pattern of immune response predominates in the pulmonary interstitium of patients with cryptogenic fibrosing alveolitis (CFA). Clin Exp Immunol
  44. (1999). SN: Pirfenidone inhibits PDGF isoforms in bleomycin hamster model of lung fibrosis at the translational level.
  45. (1998). Spiteri MA: Expression of insulinlike growth factor binding proteins in broncholaveolar lavage fluid of patients with pulmonary sarcoidosis.
  46. (1995). T: A histologially distinctive interstitial pneumonia induced by overexpression of the interleukin 6, transforming growth factor β1, or platelet-derived growth factor B gene. Proc Natl Acad Sci USA
  47. (1998). Takahashi T: Induction of apoptosis by Smad3 and down-regulation of Smad3 expression in response to TGF-beta in human normal lung epithelial cells. Oncogene
  48. (1998). Takigawa M: Inhibition of endogenous expression of connective tissue growth factor by its antisense oligonucleotide and antisense RNA suppresses proliferation and migration of vascular endothelial cells.
  49. (2000). The American Thoracic Society and the European Respiratory Society: Idiopathic pulmonary fibrosis: Diagnosis and treatment. International consensus statement. Am J Respir Crit Care Med
  50. (1999). The connective tissue growth factor/cysteinerich 61/nephroblastoma overexpressed (CCN) family. Endocrine Rev
  51. (1997). The CXC chemokines, IL-8 and IP-10, regulate angiogenic activity in idiopathic pulmonary fibrosis.
  52. (1998). TR: Keratinocyte growth factor decreases pulmonary edema, transforming growth factor-beta and platelet-derived growth factor-BB expression, and alveolar type II cell loss in bleomycin-induced lung injury. Inflammation
  53. (2000). Transforming growth factor-β-induced changes in insulin-like growth factor binding protein expression in lung fibroblasts [abstract]. Thorax
  54. (2001). Triggering the induction of myofibroblast and fibrogenesis by airway epithelial shedding.
  55. (1999). Uhal BD: Fas-induced apoptosis of alveolar epithelial cells requires ANGII generation and receptor interaction.

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.